XIAPEX (Collagenase Clostridium Histolyticum) Receives Positive CHMP Opinion
Collagenase Clostridium Histolyticum Recommended for Approval in the European Union (EU) for the Treatment of Dupuytren's Contracture in Adult Patients with a Palpable Cord
22-Dec-2010
- USA
The CHMP's positive recommendation will be reviewed by the European Commission, which has authority to approve medicines for the European Union. Pfizer anticipates a final decision from the European Commission by the end of the first quarter of 2011. The positive CHMP opinion is based on results from two pivotal studies, Collagenase Option for Reduction of Dupuytren's (CORD I and CORD II).
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.